Here, we reported that miR-17 predicted poor prognosis and added to the prognostic value of various previously identified molecular indicators in AML, such as TP53, CEBPA, NPM1, FLT3-ITD and so on. The gene discussed is CEBPA; the disease is acute myeloid leukemia.